Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Oklahoma Healthcare Wire.
Press releases published on April 8, 2025
Catalyst Pharmaceuticals Announces Health Canada’s Acceptance of AGAMREE® New Drug Submission with Priority Review for Sub-Licensee Kye Pharmaceuticals
GlobeNewswire
·
April 8, 2025
CORAL GABLES, Fla., April 08, 2025 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for …
SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.
GlobeNewswire
·
April 8, 2025
TAMPA, FL, April 08, 2025 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (the “Company”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers …
Vivex Biologics, Inc. Provides Enrollment Update for its ASCEND Study Examining Whether Supplementing Discs with VIA Disc NP™ Reduces Pain and/or Improves Function in Patients with Symptomatic Disc Degeneration
GlobeNewswire
·
April 8, 2025
MIAMI, April 08, 2025 (GLOBE NEWSWIRE) -- Vivex Biologics, Inc., a leader in developing and delivering innovative allografts, today announced the company has enrolled 50% of the patients in its ASCEND clinical trial for VIA Disc NPTM. The ASCEND study is a …
Lantern Names CTO, deepens investment in Specialty Care Platform
GlobeNewswire
·
April 8, 2025
DALLAS, April 08, 2025 (GLOBE NEWSWIRE) -- Lantern, the Specialty Care Platform connecting 6 million members with the best surgery, cancer and infusions care, has added Falko Buttler as Chief Technology Officer. Buttler brings more than two decades of …
Jupiter Neurosciences Highlights Upcoming Milestones in Shareholder Letter
GlobeNewswire
·
April 8, 2025
Strategic expansion into longevity market creates near-term commercial opportunity alongside continued clinical advancement of JOTROL™ JOTROL™ development programs remain tariff-exempt; consumer longevity line on track with negligible cost exposure Jupiter …
Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney Disease
GlobeNewswire
·
April 8, 2025
VANCOUVER, British Columbia, April 08, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage pharmaceutical development company, is pleased to announce …
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial
GlobeNewswire
·
April 8, 2025
After a single course of therapy, Descartes-08-treated participants were observed to sustain deep responses through long-term follow-up, with an average 4.8-point reduction in MG-ADL at Month 12 Deepest and most compelling sustained responses observed in …
Tilray Brands Reports Q3 Fiscal 2025 Financial Results
GlobeNewswire
·
April 8, 2025
Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. …
Theratechnologies reçoit l’approbation de la FDA pour le supplément d’approbation préalable [PAS] relatif à sa demande d’un supplément à la licence de produit biologique (sBLA) pour EGRIFTA SV(MD)
GlobeNewswire
·
April 8, 2025
L’approbation de la FDA permet une distribution sans restriction d’EGRIFTA SVMD, levant ainsi l'incertitude concernant tous les lots fabriqués L’approbation du PAS fait suite à l’approbation récente de la nouvelle formulation, EGRIFTA WRMC MONTRÉAL, 08 avr …
Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders
GlobeNewswire
·
April 8, 2025
Vancouver, Canada, April 08, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Lipella Pharmaceuticals Completes Enrollment in Phase 2a Trial of LP-310 for Oral Lichen Planus
GlobeNewswire
·
April 8, 2025
PITTSBURGH, April 08, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative therapies for unmet medical needs, today announced the …
Phonak Audéo Sphere Infinio wins Gold Edison Award for innovation in consumer solutions
GlobeNewswire
·
April 8, 2025
STÄFA, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- Phonak, a global leader in innovative hearing solutions, is proud to announce that the Phonak Audéo Sphere Infinio has been awarded the prestigious Gold Edison Award in the category of Consumer …
Nyxoah Provides Update on FDA Approvable Letter for Genio System
GlobeNewswire
·
April 8, 2025
Nyxoah Provides Update on FDA Approvable Letter for Genio System Expects to meet final FDA requirements for full PMA approval in the second quarter Mont-Saint-Guibert, Belgium – April 8, 2025, 07:00am CET / 1:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: …
BioVersys to Present BV100 Phase 2 Data at 35th ESCMID Global 2025
GlobeNewswire
·
April 8, 2025
BASEL, Switzerland, April 08, 2025 (GLOBE NEWSWIRE) -- Oral presentation on April 13, 2025, highlighting positive BV100 Phase 2 VABP trial read-out with excellent efficacy and safety data Complementary poster presentations featuring clinical …